TVRD stock soars to 52-week high, reaching $19.01

In a remarkable display of market confidence, shares of TVRD surged to a 52-week high, touching the $19.01 mark. According to InvestingPro data, the company has shown significant returns over the past week, continuing a strong six-month upward trend. This peak represents a significant milestone for the company, reflecting a period of robust trading and investor optimism. Despite the broader market’s challenges, TVRD’s stock performance stands out, with analysts projecting profitability this year despite current cash burn challenges. The company maintains a moderate debt level and its liquid assets exceed short-term obligations, providing some financial flexibility. For instance, Cara Therapeutic , a peer in the sector, has seen its value decline by 31.52% over the same period, underscoring the volatility and the specific triumphs within the pharmaceutical landscape. Investors are closely monitoring TVRD’s progress, as its current trajectory contrasts sharply with some of its competitors. For deeper insights into TVRD’s valuation and 10+ additional ProTips, explore the comprehensive analysis available on InvestingPro.

In other recent news, Cara Therapeutics (NASDAQ:TVRD), Inc. announced a 1-for-3 reverse stock split of its outstanding common stock, which will reduce the number of shares from approximately 4.6 million to about 1.5 million. This corporate move is in conjunction with a merger with Tvardi Therapeutics, Inc., which was approved by Cara’s stockholders and will see Tvardi become a wholly-owned subsidiary. The merger aims to leverage Tvardi’s therapeutic approach targeting STAT3 to address significant unmet medical needs. Additionally, Cara Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement after executing a one-for-twelve reverse stock split. The merger is expected to help Cara fulfill criteria for initial listing on the Nasdaq Capital Market, including a higher minimum bid price and stockholders’ equity requirement. Stockholders also approved the Tvardi Therapeutics 2025 Equity Incentive Plan and the 2025 Employee Stock Purchase Plan to provide incentives post-merger. Cara’s board of directors will undergo changes, with Tvardi designating the majority of the new board members. Legal action has been initiated by certain stockholders regarding the merger, but Cara has provided supplemental disclosures to address these concerns. The merger is subject to customary closing conditions, including regulatory approvals and stockholder approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.